179 related articles for article (PubMed ID: 19709356)
1. Urinary corticoid: creatinine ratios in dogs with pituitary-dependent hypercortisolism during trilostane treatment.
Galac S; Buijtels JJ; Kooistra HS
J Vet Intern Med; 2009; 23(6):1214-9. PubMed ID: 19709356
[TBL] [Abstract][Full Text] [Related]
2. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism.
Galac S; Buijtels JJCWM; Mol JA; Kooistra HS
Vet J; 2010 Jan; 183(1):75-80. PubMed ID: 19042143
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of baseline cortisol, endogenous ACTH, and cortisol/ACTH ratio to monitor trilostane treatment in dogs with pituitary-dependent hypercortisolism.
Burkhardt WA; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS
J Vet Intern Med; 2013; 27(4):919-23. PubMed ID: 23701195
[TBL] [Abstract][Full Text] [Related]
4. Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Arenas Bermejo C; Pérez Alenza D; García San José P; Llauet L; Pérez-López L; Melián C; C Feldman E
J Vet Intern Med; 2020 Jul; 34(4):1413-1422. PubMed ID: 32533623
[TBL] [Abstract][Full Text] [Related]
5. Effects of Trilostane on urinary Catecholamines and their metabolites in dogs with Hypercortisolism.
Sieber-Ruckstuhl N; Salesov E; Quante S; Riond B; Rentsch K; Hofmann-Lehmann R; Reusch C; Boretti F
BMC Vet Res; 2017 Sep; 13(1):279. PubMed ID: 28870207
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Vaughan MA; Feldman EC; Hoar BR; Nelson RW
J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
[TBL] [Abstract][Full Text] [Related]
8. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
[TBL] [Abstract][Full Text] [Related]
9. Urinary corticoid to creatinine ratios using IMMULITE 2000 XPi for diagnosis of canine hypercortisolism.
Nagata N; Sawamura H; Morishita K; Hosoya K; Yokoyama N; Sasaoka K; Sasaki N; Nakamura K; Ikenaka Y; Takiguchi M
J Vet Med Sci; 2022 Jul; 84(7):954-959. PubMed ID: 35644575
[TBL] [Abstract][Full Text] [Related]
10. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969
[TBL] [Abstract][Full Text] [Related]
11. Urinary corticoid concentrations measured by 5 different immunoassays and gas chromatography-mass spectrometry in healthy dogs and dogs with hypercortisolism at home and in the hospital.
Galeandro L; Sieber-Ruckstuhl NS; Riond B; Hartnack S; Hofmann-Lehmann R; Reusch CE; Boretti FS
J Vet Intern Med; 2014; 28(5):1433-41. PubMed ID: 25040917
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
13. Comparison of methods to monitor dogs with hypercortisolism treated with trilostane.
Golinelli S; de Marco V; Leal RO; Barbarossa A; Aniballi C; Maietti E; Tardo AM; Galac S; Fracassi F
J Vet Intern Med; 2021 Nov; 35(6):2616-2627. PubMed ID: 34672018
[TBL] [Abstract][Full Text] [Related]
14. Treatment of canine Alopecia X with trilostane.
Cerundolo R; Lloyd DH; Persechino A; Evans H; Cauvin A
Vet Dermatol; 2004 Oct; 15(5):285-93. PubMed ID: 15500480
[TBL] [Abstract][Full Text] [Related]
15. Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane.
Midence JN; Drobatz KJ; Hess RS
J Vet Intern Med; 2015; 29(6):1529-33. PubMed ID: 26374943
[TBL] [Abstract][Full Text] [Related]
16. Hyperadrenocorticism in a dog due to ectopic secretion of adrenocorticotropic hormone.
Galac S; Kooistra HS; Voorhout G; van den Ingh TS; Mol JA; van den Berg G; Meij BP
Domest Anim Endocrinol; 2005 Apr; 28(3):338-48. PubMed ID: 15760674
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162
[TBL] [Abstract][Full Text] [Related]
18. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).
Randolph JF; Toomey J; Center SA; Scarlett JM; Reimers T; Graham P; Nachreiner RF
Am J Vet Res; 1998 Mar; 59(3):258-61. PubMed ID: 9522940
[TBL] [Abstract][Full Text] [Related]
19. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012).
Woolcock AD; Bugbee AC; Creevy KE
J Am Vet Med Assoc; 2016 Apr; 248(7):814-21. PubMed ID: 27003023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
